Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.
The use of diabetes and weight-loss medications like Ozempic or Wegovy—called GLP-1 drugs—has exploded in recent years, with ...
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback